Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery

Nanomedicine

Volumn 10, Issue 8, 2015, Pages 1233-1246

  Chakravarty, Rubel ^a,b   Goel, Shreya ^a   Hong, Hao ^a   Chen, Feng ^a   Valdovinos, Hector F ^c   Hernandez, Reinier ^c   Barnhart, Todd E ^c   Cai, Weibo ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

cancer; hollow mesoporous silica nanoparticles; image guided drug delivery; PET; positron emission tomography; theranostics

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; AMINE; COPPER 64; CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO TYROSYLLYSINE); CYCLOPEPTIDE; HOLLOW MESOPOROUS SILICA NANOPARTICLE; INTEGRIN; MACROCYCLIC COMPOUND; MACROGOL; NANOCONJUGATE; SILICA NANOPARTICLE; SUNITINIB; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; ANGIOGENESIS INHIBITOR; CYCLO(ARG-GLY-ASP-TYR-LYS); DRUG CARRIER; HETEROCYCLIC COMPOUND; INDOLE DERIVATIVE; NANOPARTICLE; PYRROLE DERIVATIVE; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; NEOPLASM; NUDE MOUSE; POROSITY; PROCEDURES; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; INDOLES; MICE, NUDE; NANOPARTICLES; NEOPLASMS; PEPTIDES, CYCLIC; POROSITY; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; SILICON DIOXIDE;

EID: 84929074624     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.226     Document Type: Article

References (46)

1. Mackay JA, Li Z. Theranostic agents that co-deliver therapeutic and imaging agents? Adv. Drug Deliv. Rev. 62(11), 1003-1004 (2010).
2. Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci. Transl. Med. 5(216), 216rv214 (2013).
3. Fass L. Imaging and cancer: a review. Mol. Oncol. 2(2), 115-152 (2008).
4. Bao G, Mitragotri S, Tong S. Multifunctional nanoparticles for drug delivery and molecular imaging. Annu. Rev. Biomed. Eng. 15, 253-282 (2013).
5. Fernandez-Fernandez A, Manchanda R, Mcgoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl. Biochem. Biotechnol. 165(7-8), 1628-1651 (2011).
6. Iyer AK, He J, Amiji MM. Image-guided nanosystems for targeted delivery in cancer therapy. Curr. Med. Chem. 19(19), 3230-3240 (2012).
7. Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized nanomedicine. Clin. Cancer Res. 18(18), 4889-4894 (2012).
8. Terreno E, Uggeri F, Aime S. Image guided therapy: the advent of theranostic agents. J. Control. Release 161(2), 328-337 (2012).
9. Gary-Bobo M, Vaillant O, Maynadier M et al. Targeting multiplicity: the key factor for anti-cancer nanoparticles. Curr. Med. Chem. 20(15), 1946-1955 (2013).
10. Chen F, Hong H, Zhang Y et al. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano 7(10), 9027-9039 (2013).
11. Yang X, Hong H, Grailer JJ et al. cRGD-functionalized, dox-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32(17), 4151-4160 (2011).
12. Argyo C, Weiss V, Bräuchle C, Bein T. Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem. Mater. 26(1), 435-451 (2013).
13. Wu S-H, Mou C-Y, Lin H-P. Synthesis of mesoporous silica nanoparticles. Chem. Soc. Rev. 42(9), 3862-3875 (2013).
14. Shi S, Chen F, Cai W. Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imaging. Nanomedicine (Lond.) 8(12), 2027-2039 (2013).
15. Phillips E, Penate-Medina O, Zanzonico PB et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 6(260), 260ra149 (2014).
16. Asefa T, Tao Z. Biocompatibility of mesoporous silica nanoparticles. Chem. Res. Toxicol. 25(11), 2265-2284 (2012).
17. Kuthati Y, Sung PJ, Weng CF, Mou CY, Lee CH. Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis. J. Nanosci. Nanotechnol. 13(4), 2399-2430 (2013).
18. Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim HW, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. J. Tissue Eng. 4, 2041731413503357 (2013).
19. Mamaeva V, Sahlgren C, Linden M. Mesoporous silica nanoparticles in medicine-recent advances. Adv. Drug Deliv. Rev. 65(5), 689-702 (2013).
20. Shahbazi MA, Herranz B, Santos HA. Nanostructured porous si-based nanoparticles for targeted drug delivery. Biomatter 2(4), 296-312 (2012).
21. Tao Z, Toms BB, Goodisman J, Asefa T. Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. Chem. Res. Toxicol. 22(11), 1869-1880 (2009).
22. Hudson SP, Padera RF, Langer R, Kohane DS. The biocompatibility of mesoporous silicates. Biomaterials 29(30), 4045-4055 (2008).
23. Di Pasqua AJ, Sharma KK, Shi YL et al. Cytotoxicity of mesoporous silica nanomaterials. J. Inorg. Biochem. 102(7), 1416-1423 (2008).
24. Ma X, Zhao Y, Ng KW, Zhao Y. Integrated hollow mesoporous silica nanoparticles for target drug/sirna co-delivery. Chemistry 19(46), 15593-15603 (2013).
25. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 24(12), 1504-1534 (2012).
26. Li L, Tang F, Liu H et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 4(11), 6874-6882 (2010).
27. Luo Z, Ding X, Hu Y et al. Engineering a hollow nanocontainer platform with multifunctional molecular machines for tumor-targeted therapy in vitro and in vivo. ACS Nano 7(11), 10271-10284 (2013).
28. Ji S, Zheng Y, Shao G, Zhou Y, Liu S. Integrin alpha(v) beta(3)-targeted radiotracer (99m)tc-3p-rgd(2) useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin alpha(v)beta(3) RGD(2) therapy. Theranostics 3(11), 816-830 (2013).
29. Danhier F, Le Breton A, Preat V. Rgd-based strategies to target al.pha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9(11), 2961-2973 (2012).
30. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting rgd recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12(22), 2723-2747 (2006).
31. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. North Am. 18(5), 991-1006, vii (2004).
32. Tateishi U, Oka T, Inoue T. Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted pet tracers. Curr. Med. Chem. 19(20), 3301-3309 (2012).
33. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled rgd peptides for imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging 39(Suppl. 1), S126-S138 (2012).
34. Fang X, Chen C, Liu Z, Liu P, Zheng N. A cationic surfactant assisted selective etching strategy to hollow mesoporous silica spheres. Nanoscale 3(4), 1632-1639 (2011).
35. Chen F, Hong H, Shi S et al. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci. Rep. 4, 5080 (2014).
36. Zannetti A, Del Vecchio S, Iommelli F et al. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5). Clin. Cancer Res. 15(16), 5224-5233 (2009).
37. Sprague JE, Kitaura H, Zou W et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J. Nucl. Med. 48(2), 311-318 (2007).
38. Haubner R, Wester HJ, Burkhart F et al. Glycosylated rgd-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42(2), 326-336 (2001).
39. Chen X, Liu S, Hou Y et al. Micropet imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6(5), 350-359 (2004).
40. Maschauer S, Haubner R, Kuwert T, Prante O. (18)F-glyco-RGD peptides for pet imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation. Mol. Pharm. 11(2), 505-515 (2014).
41. Gasparini G, Brooks PC, Biganzoli E et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin. Cancer Res. 4(11), 2625-2634 (1998).
42. Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc. Natl Acad. Sci. USA 108(49), e1275-e1284 (2011).
43. Chen Y, Chen H, Shi J. Engineering of hollow mesoporous nanoparticles for biomedical applications. Adv. Porous Mater. 1(1), 34-62 (2013).
44. Chen Y, Chen H, Guo L et al. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 4(1), 529-539 (2010).
45. Cai W, Chen K, Mohamedali KA et al. Pet of vascular endothelial growth factor receptor expression. J. Nucl. Med. 47(12), 2048-2056 (2006).
46. Hong H, Yang Y, Zhang Y et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur. J. Nucl. Med. Mol. Imaging 38(7), 1335-1343 (2011).